Evidence map›Paper›PMID 40901607›Full record

ReviewWorld journal of hepatology2025

Nutrients as epigenetic modulators in metabolic dysfunction-associated steatotic liver disease.

Santiago Rodriguez, Maria Luiza Fernandes Dahlem, Carina Rossoni, Norma P Marroni, Claudio A Marroni, Sabrina Alves Fernandes

Abstract readReview
In one paragraph

Review in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Santiago RodriguezDirectorate of Postgraduate Studies in Health Sciences, Universidad de las Américas, Quito 170521, Ecuador.
Maria Luiza Fernandes DahlemDepartment of Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre 91540-000, Brazil.
Carina RossoniFaculty of Medicine, Institute of Environmental Health, University of Lisbon, Lisboa 1649-026, Portugal.
Norma P MarroniDepartment of Biologycal Sciences-Physiology, Universidade Federal do Rio Grande do Sul, Porto Alegre 91540-000, Rio Grande do Sul, Brazil.
Claudio A MarroniDepartment of Hepatology, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre 90050-170, Brazil.
Sabrina Alves FernandesSanta Casa de Porto Alegre Hospital Complex, Porto Alegre 90020-090, Rio Grande do Sul, Brazil. sabrinaafernandes@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To improve understanding of the multifaceted nature of metabolic dysfunction-associated steatotic liver disease (MASLD), the American Association for the Study of Liver Diseases, in collaboration with the European Association for the Study of the Liver and the Latin American Association for the Study of the Liver, proposed a broader and more flexible definition, highlighting the role of underlying metabolic dysfunction. MASLD represents the most common chronic liver disease worldwide; however, the impact of the disease goes beyond its epidemiological aspects. Currently, the impact on patients and healthcare systems, due to hepatic and extrahepatic complications, is significant. Recent evidence has demonstrated that epigenetic regulation plays a key role in the development and progression of MASLD. This highly sophisticated regulatory system includes DNA methylation, histone modification, chromatin remodeling, and modulation of non-coding RNA, without causing changes in the primary DNA sequence. Diet, particularly the Westernized diet (characterized by high levels of processed foods, fats, and sugars, but deficient in vitamins and minerals), contributes to the pathogenesis of MASLD through epigenetic modulation at multiple levels. Given the association between diet, epigenetics, and MASLD, this review aims to present some micronutrients and their importance in the prevention and/or treatment of metabolically dysfunction-associated steatotic liver disease.

Indexed as

EpigeneticsHepatic steatosisMetabolic dysfunction-associated steatotic liver diseaseNutrigeneticsNutrition

Identifiers

PMID40901607
PMCPMC12400399

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.